Seiberl, M.; Feige, J.; Hilpold, P.; Hitzl, W.; Machegger, L.; Buchmann, A.; Khalil, M.; Trinka, E.; Harrer, A.; Wipfler, P.;
et al. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. Int. J. Mol. Sci. 2023, 24, 4067.
https://doi.org/10.3390/ijms24044067
AMA Style
Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A, Khalil M, Trinka E, Harrer A, Wipfler P,
et al. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences. 2023; 24(4):4067.
https://doi.org/10.3390/ijms24044067
Chicago/Turabian Style
Seiberl, Michael, Julia Feige, Patrick Hilpold, Wolfgang Hitzl, Lukas Machegger, Arabella Buchmann, Michael Khalil, Eugen Trinka, Andrea Harrer, Peter Wipfler,
and et al. 2023. "Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting" International Journal of Molecular Sciences 24, no. 4: 4067.
https://doi.org/10.3390/ijms24044067
APA Style
Seiberl, M., Feige, J., Hilpold, P., Hitzl, W., Machegger, L., Buchmann, A., Khalil, M., Trinka, E., Harrer, A., Wipfler, P., & Moser, T.
(2023). Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences, 24(4), 4067.
https://doi.org/10.3390/ijms24044067
